These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 11132243)

  • 21. Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions.
    Sekine Y; Rikihisa T; Ogata H; Echizen H; Arakawa Y
    Eur J Clin Pharmacol; 1999 Oct; 55(8):583-7. PubMed ID: 10541776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine versus other atypical antipsychotics for schizophrenia.
    Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of the novel antipsychotic drug amperozide and its metabolite FG5620 with central nervous system receptors and monoamine uptake sites: relation to behavioral and clinical effects.
    Svartengren J; Pettersson E; Björk A
    Biol Psychiatry; 1997 Aug; 42(4):247-59. PubMed ID: 9270901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
    Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA
    Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects.
    Richelson E
    J Clin Psychiatry; 1984 Aug; 45(8):331-6. PubMed ID: 6146602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Receptor pharmacology of neuroleptics: relation to clinical effects.
    Richelson E
    J Clin Psychiatry; 1999; 60 Suppl 10():5-14. PubMed ID: 10340682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.
    Ninan I; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):603-8. PubMed ID: 10669905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical pharmacology of neuroleptics: focus on new generation compounds.
    Richelson E
    J Clin Psychiatry; 1996; 57 Suppl 11():4-11. PubMed ID: 8941166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation.
    Theisen FM; Haberhausen M; Firnges MA; Gregory P; Reinders JH; Remschmidt H; Hebebrand J; Antel J
    Pharmacogenomics J; 2007 Aug; 7(4):275-81. PubMed ID: 16983399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S-16924, a novel, potential antipsychotic with marked serotonin1A agonist properties. IV. A drug discrimination comparison with clozapine.
    Millan MJ; Schreiber R; Monneyron S; Denorme B; Melon C; Queriaux S; Dekeyne A
    J Pharmacol Exp Ther; 1999 Apr; 289(1):427-36. PubMed ID: 10087034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
    Kalkman HO; Loetscher E
    Eur J Pharmacol; 2003 Feb; 462(1-3):33-40. PubMed ID: 12591093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
    Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroleptic binding to muscarinic M2 receptors of normal human heart in vitro and comparison with binding to M1 and dopamine D2 receptors of brain.
    Neeper R; Richelson E; Nelson A
    Neuropharmacology; 1991 May; 30(5):527-9. PubMed ID: 1678146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radioreceptor binding profile of the atypical antipsychotic olanzapine.
    Bymaster FP; Calligaro DO; Falcone JF; Marsh RD; Moore NA; Tye NC; Seeman P; Wong DT
    Neuropsychopharmacology; 1996 Feb; 14(2):87-96. PubMed ID: 8822531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroleptic binding to human brain receptors: relation to clinical effects.
    Richelson E
    Ann N Y Acad Sci; 1988; 537():435-42. PubMed ID: 2904784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone.
    Subramanian N; Kalkman HO
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Apr; 26(3):553-60. PubMed ID: 11999907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
    Herrick-Davis K; Grinde E; Teitler M
    J Pharmacol Exp Ther; 2000 Oct; 295(1):226-32. PubMed ID: 10991983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous in-vivo receptor occupancy assays for serotonin 1A, 2A, and dopamine 2 receptors with the use of non-radiolabelled tracers: Proposed method in screening antipsychotics.
    Thentu JB; Nirogi R; Bhyrapuneni G; Ajjala DR; Aleti RR; Palacharla RC
    J Pharmacol Toxicol Methods; 2017; 85():22-28. PubMed ID: 28063918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine.
    Uchida S; Kato Y; Hirano K; Kagawa Y; Yamada S
    Life Sci; 2007 Apr; 80(17):1635-40. PubMed ID: 17316700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.